

## LABORATORIOS FARMACÉUTICOS ROVI, S.A

Julián Camarillo, 35 Télefono 91 375 62 30 28037 MADRID

Fax. 91 304 78 81 Dir. Teleg.: ROBRISA Apartado de Correos 35.027 E-mail: rovi@rovi.es Http://www.rovi.es

## NANOTECHNOLOGY POLICY

Nanotechnology is the term given to those areas of science and engineering where phenomena that take place at dimensions in the nanometre scale are utilised in the design, characterization, production and application of materials, structures, devices and systems.

There is growing awareness of the potential health and social benefits of using nanotechnology in medicine (treatment for diseases, drug release, etc) focused on improving the quality of life of the patients.

However, ROVI Group acknowledges the singularity taking place at the nanoscale may be quite different to those occurring at larger dimensions so these newly identified processes and their products may expose humans, and the environment in general, to new health risks, possibly involving quite different mechanisms of interference with the physiology of human and environmental species.

ROVI believes that nanotechnology may be a benefit for healthcare, but it is also aware of the risk that can entail, therefore, is committed to conduct responsible and science-based research in case these emerging technologies come under study. Current regulatory framework, is robust and provides guidelines of risk management, but continuous definition and scientific advice on regulations governing the development and marketing of nanoproducts is needed and being developed.

Rovi pharmaceutical commercialized products have not been developed with this new emerging technology. However, our R&D programs, may introduce these as an opportunity. In such development programs close collaboration with Authorities and ensuring compliance with current regulatory framework is ensured, highly committing ROVI Group with its Policy.

APPROVED BY

Juan López-Belmonte Encina

C.E.O